Literature DB >> 27084711

Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization.

Haruyuki Takaki1, Naoko Imai2, Thomas T Contessa3, Govindarajan Srimathveeravalli3, Anne M Covey3, George I Getrajdman3, Karen T Brown3, Stephen B Solomon3, Joseph P Erinjeri3.   

Abstract

PURPOSE: To evaluate changes in T-cell populations in peripheral blood after bland hepatic artery embolization (HAE).
MATERIALS AND METHODS: Bland HAE was performed in 12 patients to treat primary (n = 5) or metastatic (n = 7) liver tumors, using microspheres and polyvinyl alcohol (n = 8) or microspheres alone (n = 4). Patient peripheral blood samples were collected within 1 month before HAE, within 1 week after HAE (early period after HAE), and 2-8 weeks after HAE (follow-up period). Peripheral blood populations of cytotoxic T lymphocytes, CD4(+) T cells, type 1 helper T cells (Th1) and type 2 helper T cells (Th2), and regulatory T cells (Treg) were evaluated using flow cytometry. Changes in T-cell populations before and after bland HAE were compared using paired t tests.
RESULTS: Peripheral blood CD4(+) T-cell populations decreased significantly in the early period after HAE (44.0% ± 2.2 to 34.4% ± 3.6, P < .01) and in the follow-up period (44.0% ± 2.2 to 36.3% ± 3.0, P < .01). Among the individual CD4(+) T-cell subtypes, Treg (2.5% ± 0.3 to 1.7% ± 0.2, P < .02) and Th1 (8.1% ± 1.8 to 5.6% ± 1.6, P < .02) decreased significantly in the early period after HAE only. The presence of extrahepatic disease was associated with decreasing Treg (P < .04).
CONCLUSIONS: After HAE, the peripheral blood T-cell environment is changed with decreases in Treg and Th1.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27084711      PMCID: PMC5039109          DOI: 10.1016/j.jvir.2016.01.150

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  29 in total

1.  Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Zhi-Liang Huang; Jun Luo; Min-Shan Chen; Jin-Qing Li; Ming Shi
Journal:  J Vasc Interv Radiol       Date:  2011-05       Impact factor: 3.464

2.  Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients.

Authors:  Hideyuki Ubukata; Gyou Motohashi; Takanobu Tabuchi; Hiroyuki Nagata; Satoru Konishi; Takafumi Tabuchi
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

3.  CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Authors:  Andrew J Rech; Rosemarie Mick; Sunil Martin; Adri Recio; Nicole A Aqui; Daniel J Powell; Theresa A Colligon; Jennifer A Trosko; Leah I Leinbach; Charles H Pletcher; Carol K Tweed; Angela DeMichele; Kevin R Fox; Susan M Domchek; James L Riley; Robert H Vonderheide
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

Review 4.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer.

Authors:  Zhengbin Shen; Shuang Zhou; Yanna Wang; Ri-lun Li; Cuiping Zhong; Chunmin Liang; Yihong Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-11       Impact factor: 4.553

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor.

Authors:  Y Matsuda; S Kawata; T Nagase; Y Maeda; E Yamasaki; S Kiso; H Ishiguro; Y Matsuzawa
Journal:  Cancer       Date:  1994-01-01       Impact factor: 6.860

Review 8.  Th1 cytokine-based immunotherapy for cancer.

Authors:  Hong-Mei Xu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2014-10

9.  The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

Authors:  Claudia C Preston; Matthew J Maurer; Ann L Oberg; Daniel W Visscher; Kimberly R Kalli; Lynn C Hartmann; Ellen L Goode; Keith L Knutson
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.

Authors:  S Han; C Zhang; Q Li; J Dong; Y Liu; Y Huang; T Jiang; A Wu
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640

View more
  9 in total

Review 1.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 2.  Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.

Authors:  Nathan X Chai; Julius Chapiro
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

3.  Adjuvant Medications That Improve Survival after Locoregional Therapy.

Authors:  F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Karen T Brown; Joseph P Erinjeri; Constantinos T Sofocleous; James J Harding; Stephen B Solomon
Journal:  J Vasc Interv Radiol       Date:  2017-05-17       Impact factor: 3.464

Review 4.  Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Authors:  Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg
Journal:  Radiology       Date:  2019-04-23       Impact factor: 11.105

5.  Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.

Authors:  Yanqiao Ren; Ziyi Liu; Joyman Makamure; Xuefeng Kan; Songlin Song; Yiming Liu; Kun Qian; Chuansheng Zheng; Bin Liang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment.

Authors:  Tonglei Fang; Junyuan Xiao; Yiran Zhang; Haiyan Hu; Yueqi Zhu; Yingsheng Cheng
Journal:  Quant Imaging Med Surg       Date:  2021-06

Review 7.  Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques.

Authors:  Francois H Cornelis; Stephen B Solomon
Journal:  J Nucl Med       Date:  2018-10-25       Impact factor: 10.057

8.  Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.

Authors:  Fei Yang; Gui-Li Xu; Jin-Tao Huang; Yu Yin; Wei Xiang; Bin-Yan Zhong; Wan-Ci Li; Jian Shen; Shuai Zhang; Jun Yang; Hong Peng Sun; Wan-Sheng Wang; Xiao-Li Zhu
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

Review 9.  Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.

Authors:  Liwei Sun; Xuelong Xu; Fanguang Meng; Qian Liu; Hankang Wang; Xiaodong Li; Guijie Li; Feng Chen
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.